Clinical trial
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
NCT00139152 · Creighton University, Other · Completed
Key facts
| NCT number | NCT00139152 |
|---|---|
| Title | Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair |
| Official title | Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of Lung Disease After Treatment With Xolair |
| Lead sponsor | Creighton University, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Lung Disease |
| Intervention type | Drug |
| Interventions | Placebo, Xolair |
| Enrollment | 65 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Aug 31, 2005 |
| Last update posted | Jan 7, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: